Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery

Rhea-AI Summary

Lunai Bioworks (NASDAQ:RENB) has launched a groundbreaking transformer-based platform that integrates biological risk intelligence into large language model (LLM) pipelines. The platform leverages virtual chemical screening to identify potentially toxic compounds, serving dual purposes: accelerating therapeutic discovery and providing biodefense capabilities.

The company's platform, powered by extensive in vivo neurotoxicity datasets from zebrafish-based assays, addresses the growing concern of generative AI potentially being misused to create harmful biological or chemical compounds. The technology embeds a proprietary neurotoxicity intelligence layer into LLM workflows, ensuring safety while maintaining innovation potential in both pharmaceutical development and biodefense markets.

Positive

• Proprietary neurotoxicity datasets from thousands of zebrafish-based assays provide unique competitive advantage
• Dual market opportunity in both drug discovery AI and biodefense AI sectors
• Strong technological moat with transformer-based safety intelligence system
• Strategic positioning for partnerships with pharmaceutical, biotech, and government entities

Negative

• No current revenue or partnership metrics disclosed
• Early-stage technology without proven commercial implementation

Proprietary safety intelligence creates dual value: faster therapeutic development and biodefense.

LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 9, 2025 / Lunai Bioworks Inc. (NASDAQ:RENB), an AI-powered drug discovery and biodefense company, today announced the launch of a transformer-based platform that embeds biological risk intelligence directly into large language model (LLM) pipelines. This breakthrough uses virtual chemical screening to identify novel compounds as being potentially toxic, expediting therapeutic discovery and development. Through its application, this platform also addresses a growing security concern, the misuse of generative AI in designing hazardous biological or chemical compounds.

With generative AI rapidly transforming healthcare and biotech, investors and regulators are increasingly focused on the dual-use challenge: the same algorithms that discover new medicines could also be exploited to create novel toxins. Lunai Bioworks' solution embeds a proprietary neurotoxicity intelligence layer into LLM workflows, ensuring safety while preserving innovation.

"This is all about understanding and predicting risk," said Dr. Gabe Musso, Chief Scientific Officer of Lunai Bioworks' wholly owned subsidiary Biosymetrics Inc. "Our platform accelerates the discovery of safe, effective therapeutics, with the added benefit of being able to safeguard against the creation of novel chemical threats. That's a major differentiator for our partners."

Key investment highlights:

• Exclusive Data Advantage: Powered by our large in vivo neurotoxicity datasets, collected from thousands of zebrafish-based assays, offering biological realism unmatched by public or in silico-only resources.

• Defensible Technology: Transformer-based safety intelligence acts as a real-time safeguard within generative AI pipelines, creating a strong moat in a high-growth sector.

• Massive Market Opportunity: Supports dual markets - multi-billion-dollar drug discovery AI and biodefense AI - both undergoing rapid expansion driven by government, pharma, and biotech demand.

• Alignment with Global Priorities: Addresses urgent calls from regulators, governments, and AI safety organizations for robust safeguards against AI-enabled biothreats.

• Scalable Partnerships: Positioned for integration with pharmaceutical pipelines, biotech platforms, and government biodefense programs.

By merging biodefense preparedness with pharmaceutical innovation, Lunai Bioworks Inc. is building a dual-purpose transformer for safe generative biology. This positions the company as a category leader at the convergence of AI, healthcare, and security.

About Lunai Bioworks

Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.

Media Contact:

David Weinstein
Chief Executive Officer
investors@renovaro.com
www.renovarogroup.com

SOURCE: Lunai Bioworks Inc.

View the original press release on ACCESS Newswire

FAQ

What is Lunai Bioworks' (NASDAQ:RENB) new AI platform and how does it work?

Lunai Bioworks' new platform is a transformer-based system that embeds biological risk intelligence into LLM pipelines, using virtual chemical screening to identify potentially toxic compounds for both drug discovery and biodefense purposes.

What competitive advantage does Lunai Bioworks (RENB) have in the AI drug discovery market?

The company's competitive advantage comes from its exclusive in vivo neurotoxicity datasets from thousands of zebrafish-based assays, providing biological realism that surpasses public or in silico-only resources.

How does Lunai Bioworks' platform address AI safety concerns in drug discovery?

The platform integrates a proprietary neurotoxicity intelligence layer into LLM workflows, preventing the potential misuse of generative AI in creating harmful biological or chemical compounds while enabling therapeutic innovation.

What are the target markets for Lunai Bioworks' (NASDAQ:RENB) new platform?

The platform targets two major markets: the multi-billion-dollar drug discovery AI sector and the biodefense AI sector, both experiencing rapid growth driven by government, pharmaceutical, and biotech demand.

Who is leading the scientific development at Lunai Bioworks?

Dr. Gabe Musso, Chief Scientific Officer of Lunai Bioworks' subsidiary Biosymetrics Inc., leads the scientific development of the platform.